Anastasios Dimou

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

Douglas B. Johnson, Jennifer Bordeaux, Ju Young Kim et al. · Clinical Cancer Research · 2018 · 176 citations

Life Sciences, Immunology, Oncology +17

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Ferdinandos Skoulidis, Kathryn C. Arbour, Matthew D. Hellmann et al. · Journal of Clinical Oncology · 2019 · 101 citations

Medicine, Oncology, Pharmacology +17

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

Terry L. Ng, Yiwei Liu, Anastasios Dimou et al. · Cancer · 2018 · 82 citations · Full text

Medicine, Oncology, Pharmacology +15

ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events

Terry L. Ng, Derek Smith, Rao Mushtaq et al. · Journal of Thoracic Oncology · 2018 · 74 citations

Medicine, Genetics, Molecular Genetics +9

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer

Anastasios Dimou, Konstantinos N. Syrigos, Muhammad Wasif Saif · Therapeutic Advances in Medical Oncology · 2012 · 67 citations

Medicine, Oncology, Pharmacology +16